Stocks
Funds
Screener
Sectors
Watchlists
NTRA

NTRA - Natera Inc Stock Price, Fair Value and News

$161.88+3.79 (+2.40%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

NTRA Price Action

Last 7 days

-2.8%


Last 30 days

-3.6%


Last 90 days

26.7%


Trailing 12 Months

168.5%

NTRA RSI Chart

NTRA Valuation

Market Cap

21.4B

Price/Earnings (Trailing)

-99.55

Price/Sales (Trailing)

13.95

EV/EBITDA

-120.59

Price/Free Cashflow

-644.01

NTRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NTRA Fundamentals

NTRA Revenue

Revenue (TTM)

1.5B

Rev. Growth (Yr)

63.9%

Rev. Growth (Qtr)

6.39%

NTRA Earnings

Earnings (TTM)

-214.7M

Earnings Growth (Yr)

71.02%

Earnings Growth (Qtr)

15.67%

NTRA Profitability

EBT Margin

-13.87%

Return on Equity

-24.44%

Return on Assets

-13.49%

Free Cashflow Yield

-0.16%

NTRA Investor Care

Shares Dilution (1Y)

9.88%

Diluted EPS (TTM)

-1.75

NTRA Alerts

  • 8 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.2B1.4B1.5B0
2023867.8M931.0M988.7M1.1B
2022667.3M723.5M776.0M820.2M
2021449.3M504.9M564.8M625.5M
2020329.5M341.6M361.9M391.0M
2019262.1M273.4M286.1M302.3M
2018222.6M233.4M242.7M257.7M
2017204.6M204.9M206.9M209.6M
2016204.8M211.7M220.7M217.1M
2015179.4M188.7M187.3M190.4M
201481.2M107.2M133.3M159.3M
201300055.2M
NTRA
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
 CEO
 WEBSITEnatera.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES2958

Natera Inc Frequently Asked Questions


What is the ticker symbol for Natera Inc? What does NTRA stand for in stocks?

NTRA is the stock ticker symbol of Natera Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Natera Inc (NTRA)?

As of Fri Dec 20 2024, market cap of Natera Inc is 21.37 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NTRA stock?

You can check NTRA's fair value in chart for subscribers.

Is Natera Inc a good stock to buy?

The fair value guage provides a quick view whether NTRA is over valued or under valued. Whether Natera Inc is cheap or expensive depends on the assumptions which impact Natera Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTRA.

What is Natera Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, NTRA's PE ratio (Price to Earnings) is -99.55 and Price to Sales (PS) ratio is 13.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTRA PE ratio will change depending on the future growth rate expectations of investors.